Efficacy and Safety of Repetitive Transcranial Magnetic Stimulation (rTMS) in Alzheimer's disease: An Updated Meta-analysis of 35 Randomized Sham-controlled Trials
In brief
Repetitive brain stimulation improves cognition in Alzheimer's, but raises adverse events
Across 35 trials involving 1,746 patients, repetitive transcranial magnetic stimulation improved cognitive scores versus sham and also reduced neuropsychiatric symptoms and dementia severity; it did not improve daily function or depression. Overall adverse events were more frequent, though generally mild. Short follow-up and varied treatment protocols leave the durability of benefits and best approach uncertain.
- Journal
- Neuromodulation : journal of the International Neuromodulation Society (Q1)
- Published
- 25 September 2026
- Study design
- Systematic review / meta-analysis of RCTs
- Evidence level
- Level 1, High (CEBM 1a)
- Authors
- Omar Khaled Abdelsalam, Nada Mosad, Moaz Elsayed Abouelmagd, Mark Messak, Nereen A Almosilhy, Ahmed Harb, et al.
- PMID
- 43002148
- DOI
- 10.1016/j.neurom.2026.09.008
Why clinicians should know about it
- Picked for Neurology (clinical) (top studies of the week, 15 November 2026): Meta-analysis evaluates rTMS efficacy and safety in Alzheimer disease
Abstract
INTRODUCTION: Alzheimer's disease (AD) is the leading cause of dementia worldwide, causing progressive cognitive and functional decline that adversely affects patients' independence and increases caregivers' burden. Repetitive transcranial magnetic stimulation (rTMS) is a non-invasive neuromodulation technique that is being increasingly studied in AD; however, trials differ widely in targeted regions, stimulation parameters, and outcome measures, limiting clinical guidance. However, existing meta-analyses are limited by conflicting outcome findings, inconsistent protocol evaluations (e.g., rTMS vs. Intermittent Theta Burst Stimulation (iTBS), a modified version of rTMS), and a lack of formal Grading of Recommendations Assessment, Development, and Evaluation (GRADE) certainty assessments. This updated meta-analysis integrates subgroup, trial-sequential, and GRADE analyses to address these gaps and provide clear clinical guidance. MATERIALS AND METHODS: We systematically searched PubMed, Scopus, Web of Science, and the Cochrane Library for randomized controlled trials (RCTs) assessing the efficacy and safety of rTMS versus sham in adults with Alzheimer's disease. The primary outcome was global cognition, measured by the Mini-Mental State Examination (MMSE) or Alzheimer's disease assessment scale-cognitive subscale (ADAS-Cog). Secondary outcomes included neuropsychiatric symptoms, functional status, depression, dementia severity, and adverse events. We performed random-effects meta-analysis in R, with additional sensitivity analyses, subgroup analyses (stimulation type: rTMS and iTBS; AD stage; stimulation area; frequency; therapeutic approach; intervention duration; follow-up duration), trial sequential analysis (TSA), publication bias assessment, and GRADE certainty evaluation. RESULTS: The updated meta-analysis included 35 RCTs (n = 1746 patients) with Alzheimer's disease. Compared with sham, active rTMS was associated with a moderate improvement in global cognition (standardized mean difference (SMD) 0.57, 95% CI: 0.33, 0.81; p < 0.0001; moderate certainty); however, subgroup analysis revealed that iTBS showed no statistically significant improvement. Active rTMS was also associated with clinically meaningful reductions in neuropsychiatric symptoms (mean difference (MD) -3.28, 95% CI: -5.09, -1.46) and dementia severity (MD -0.29, 95% CI: -0.57, -0.01). No significant benefit was observed for functional status or depression. Headache, scalp discomfort, and fatigue did not differ between the groups, but active rTMS carried a higher overall rate of adverse events (RR 1.51, 95% CI: 1.07, 2.14; p = 0.02). CONCLUSION: Active rTMS appears to provide short-term cognitive benefits in Alzheimer's disease, with additional improvements in neuropsychiatric symptoms and dementia severity. Although adverse events were more frequent overall, they were generally mild and well-tolerated. Protocol heterogeneity and limited long-term follow-up prevent definitive recommendations for routine clinical use; larger, standardized, adequately powered RCTs are needed to define optimal targets, stimulation parameters, durability, and likely responder subgroups.
Abstract as published, via PubMed.
For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.